Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy
Background Based on data from two multicenter, phase III clinical trials (Studies 301 and 305), eribulin (a microtubule dynamics inhibitor) is indicated in the European Union (EU) for patients with locally advanced or metastatic breast cancer (MBC) after ≥1 prior chemotherapy for advanced disease, i...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
13 May 2016
|
| In: |
Annals of oncology
Year: 2016, Jahrgang: 27, Heft: 8, Pages: 1525-1531 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw203 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1093/annonc/mdw203 Verlag, Volltext: https://academic.oup.com/annonc/article/27/8/1525/1741475 
|
| Verfasserangaben: | X. Pivot, F. Marmé, R. Koenigsberg, M. Guo, E. Berrak & A. Wolfer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1571444238 | ||
| 003 | DE-627 | ||
| 005 | 20230428184854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180326s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdw203 |2 doi | |
| 035 | |a (DE-627)1571444238 | ||
| 035 | |a (DE-576)501444238 | ||
| 035 | |a (DE-599)BSZ501444238 | ||
| 035 | |a (OCoLC)1340995396 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pivot, Xavier |e VerfasserIn |0 (DE-588)1155130502 |0 (DE-627)1016504047 |0 (DE-576)501443800 |4 aut | |
| 245 | 1 | 0 | |a Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy |c X. Pivot, F. Marmé, R. Koenigsberg, M. Guo, E. Berrak & A. Wolfer |
| 264 | 1 | |c 13 May 2016 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.03.2018 | ||
| 520 | |a Background Based on data from two multicenter, phase III clinical trials (Studies 301 and 305), eribulin (a microtubule dynamics inhibitor) is indicated in the European Union (EU) for patients with locally advanced or metastatic breast cancer (MBC) after ≥1 prior chemotherapy for advanced disease, including an anthracycline and a taxane in either the adjuvant or metastatic setting. Data from Studies 305 and 301 were pooled to investigate the efficacy of eribulin in various subgroups of patients who matched the EU label, including those with human epidermal growth factor receptor 2 (HER2)-negative and triple-negative disease.Patients and methodsIn Study 305 (NCT00388726), patients were randomized 2:1 to eribulin mesylate 1.4 mg/m2 (equivalent to eribulin 1.23 mg/m2 [expressed as free base]) intravenously on days 1 and 8 every 21 days] or treatment of physician's choice after 2-5 prior chemotherapies (≥2 for advanced disease), including an anthracycline and a taxane (in early/advanced setting). In Study 301 (NCT00337103), patients were randomized 1:1 to eribulin (as above) or capecitabine (1.25 g/m2 orally twice daily on days 1-14 every 21 days) following ≤3 prior chemotherapies (≤2 for advanced disease), including an anthracycline and a taxane. Efficacy end points were investigated in the intent-to-treat population and subgroups, pooled as discussed above.ResultsOverall, 1644 patients were included (eribulin: 946; control: 698); baseline characteristics were well matched. Overall survival was significantly longer with eribulin versus control (P < 0.01), as were progression-free survival and clinical benefit rate (both P < 0.05). Significant survival benefits with eribulin versus control were observed in a wide range of patient subgroups, including HER2-negative or triple-negative disease (all P < 0.05).Conclusion Our findings underline the survival benefit achieved by eribulin used according to EU label in the overall MBC population and in various subgroups of interest, including patients with HER2-negative and triple-negative disease. | ||
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 27(2016), 8, Seite 1525-1531 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy |
| 773 | 1 | 8 | |g volume:27 |g year:2016 |g number:8 |g pages:1525-1531 |g extent:7 |a Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdw203 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/annonc/article/27/8/1525/1741475 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180326 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 910000 |d 910400 |e 910000PM132561972 |e 910400PM132561972 |k 0/910000/ |k 1/910000/910400/ |p 2 | ||
| 999 | |a KXP-PPN1571444238 |e 3004331012 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"given":"Xavier","role":"aut","display":"Pivot, Xavier","family":"Pivot"},{"display":"Marmé, Frederik","family":"Marmé","role":"aut","given":"Frederik"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"13 May 2016"}],"note":["Gesehen am 26.03.2018"],"title":[{"title":"Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy","title_sort":"Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy"}],"id":{"doi":["10.1093/annonc/mdw203"],"eki":["1571444238"]},"name":{"displayForm":["X. Pivot, F. Marmé, R. Koenigsberg, M. Guo, E. Berrak & A. Wolfer"]},"physDesc":[{"extent":"7 S."}],"recId":"1571444238","relHost":[{"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"part":{"extent":"7","volume":"27","year":"2016","pages":"1525-1531","issue":"8","text":"27(2016), 8, Seite 1525-1531"},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapyAnnals of oncology","title":[{"subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology","title":"Annals of oncology"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"origin":[{"publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedKey":"1990","dateIssuedDisp":"1990-"}],"pubHistory":["1.1990 -"],"id":{"zdb":["2003498-2"],"issn":["1569-8041"],"eki":["320428796"]},"recId":"320428796","physDesc":[{"extent":"Online-Ressource"}]}]} | ||
| SRT | |a PIVOTXAVIEPOOLEDANAL1320 | ||